2025
Assessing the impact of revising MenACWY vaccination schedule for adolescents in the United States: a modelling study
Shoukat A, Wells C, Shin T, Potter-Schwartz L, Galvani A, Moghadas S. Assessing the impact of revising MenACWY vaccination schedule for adolescents in the United States: a modelling study. The Lancet Regional Health - Americas 2025, 44: 101033. PMID: 40046840, PMCID: PMC11880592, DOI: 10.1016/j.lana.2025.101033.Peer-Reviewed Original ResearchInvasive meningococcal diseaseInvasive meningococcal disease casesVaccination scheduleVaccine uptakeAlternative schedulesMenACWY vaccination programCase fatality rateHigh-risk adolescentsVaccine introductionBooster doseIMD casesSerogroup CCompare outcomesMenACWY vaccineAsymptomatic infectionImmunization PracticesMeningococcal diseaseVaccine effectivenessIMD incidenceDoseSerogroups AVaccineStudy periodVaccination programIncrease vaccine uptake
2024
Evaluation of Strategies for Transitioning to Annual SARS-CoV-2 Vaccination Campaigns in the United States.
Wells C, Pandey A, Moghadas S, Fitzpatrick M, Singer B, Galvani A. Evaluation of Strategies for Transitioning to Annual SARS-CoV-2 Vaccination Campaigns in the United States. Annals Of Internal Medicine 2024, 177: 609-617. PMID: 38527289, DOI: 10.7326/m23-2451.Peer-Reviewed Original ResearchSARS-CoV-2 vaccination campaignSARS-CoV-2Centers for Disease Control and PreventionDisease Control and PreventionSARS-CoV-2 vaccinesHealth care costsVaccine-acquired immunityFood and Drug AdministrationU.S. Food and Drug AdministrationControl and PreventionNational Institutes of HealthVaccination campaignInfluenza vaccineInitial doseInstitutes of HealthSARS-CoV-2 variantsBooster doseImmune evasionDrug AdministrationUnited StatesNotsew Orm Sands FoundationDoseHealthPopulation immunityNational Institute
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply